Çalapkulu, Murat2023-03-232023-03-232019-01-17Çalapkulu, M. vd. (2019). ''Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center''. Diabetes & Metabolic Syndrome-Clinical Research & Reviews, 13(2), 1031-1034.1871-40211878-0334https://doi.org/10.1016/j.dsx.2019.01.016https://www.sciencedirect.com/science/article/pii/S1871402118306313http://hdl.handle.net/11452/31723Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus which increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin (10 mg) on lipid profile were investigated retrospectively. Methods: A total of thirty-one type 2 diabetic patients with HbA1c level between 6,5% and 13%, aged 45 -80 years and whose body mass index higher than 20 kg/m(2) were enrolled to the study. Data before dapagliflozin treatment and three and six months results were recorded. Results: Dapagliflozin reduced HbA1c levels by 0,9% at 3 months and 0,79% at 6 months. Total cholesterol level decreased 17,6 mg/dl, LDL cholesterol level decreased 13,4 mg/dl and triglyceride level by 25.9mg/dl at the 6th months and it is observed that there is no serious side effect on the usage for 6 months. Conclusion: There are conflicting results about the effect of SGLT2 inhibitors on the lipid profile in the literature. According to our data, dapagliflozin has positive effects on lipid profile as weight and glycemic control and it is well tolerated. Therefore, dapagliflozin therapy is beneficial because of the positive change in lipid profile and weight loss in diabetic patients with overweight and hyperlipidemia.eninfo:eu-repo/semantics/closedAccessEndocrinology & metabolismType 2 diabetesDapagliflozinLipid profileLdlTotal cholesterolTriglycerideGlycemic controlTherapyAgedAged, 80 and overBenzhydryl compoundsBiomarkersBlood glucoseDiabetes mellitus, type 2FemaleFollow-up studiesGlucosidesGlycated hemoglobin AHumansLipidsMaleMiddle AgedPrognosisRetrospective studiesSodium-glucose transporter 2 inhibitorsReview0004665493000222-s2.0-850603105251031103413231336439Endocrinology & metabolismAntidiabetic Agent; Empagliflozin; Electron Microprobe AnalysisCholesterolDapagliflozinHemoglobin A1cLow density lipoprotein cholesterolTriacylglycerol2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triolVenzhydryl derivativeBiological markerGlucosideGlycosylated hemoglobinHemoglobin A1c protein, humanLipidAdultAgedBody massBody weight lossCholesterol blood levelClinical articleDiabetic patientDrug effectDrug tolerabilityFemaleGlucose urine levelGlycemic controlHumanHyperlipidemiaLipid analysisLow density lipoprotein cholesterol levelMaleNon insulin dependent diabetes mellitusObesityPriority journalRetrospective studyReviewTriacylglycerol levelBloodClinical trialFollow upGlucose blood levelMiddle agedNon insulin dependent diabetes mellitusPathologyPrognosisVery elderly